38
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Histoplasma capsulatum: More Widespread than Previously Thought

      editorial

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Histoplasmosis is an endemic mycosis caused by a dimorphic fungus with two distinct varieties pathogenic for humans: Histoplasma capsulatum var. capsulatum and H. capsulatum var. duboisii. The latter is known to be restricted to sub-Saharan Africa, whereas the former is distributed worldwide. However, general textbooks of medical mycology when considering the geographic distribution of H. capsulatum var. capsulatum either refer only to “eastern United States (Ohio, Mississippi, and St. Lawrence River valleys) and most of Latin America,”1 or indicate that “isolated cases have been reported also from Southeast Asia and Africa.”2 In this issue of the Journal, Wang and others3 describe an autochthonous case of disseminated progressive histoplasmosis (DPH) observed in a young human immunodeficiency virus (HIV)-negative Chinese man. This report adds to the growing evidence from epidemiological surveys using histoplasmin skin tests,4 case reports,5 and a recent review of the literature6 (mostly of works written in Chinese) indicating that some areas of China should be included among those with medium-high endemicity for H. capsulatum. However, because China is one of the largest countries in the world, epidemiological information for clinicians should take into account which specific areas are involved. In this regard the histoplasmin skin test survey conducted by Zhao and others,4 showed an overall reactivity of 9.0% among 735 healthy volunteers and patients with lung diseases, with the highest prevalence observed in Hunan (8.9%) and Jiangsu (15.1%) provinces. In good agreement, in a review of 300 cases of histoplasmosis diagnosed in China (75% considered autochthonous),6 the geographical distribution of patients was 27.7% from Yunnan, 9.3% from Jiangsu and Hunan, 8.7% from Hubei and 7.3% from Sichuan. Another histoplasmin skin test survey conducted on 271 healthy students from Sichuan province showed a prevalence ranging from 6% to 35%, with the highest recorded in the southern part of the province.7 Overall, nearly 82% of all reviewed cases of histoplasmosis from China were reported from nine provinces through which the Yangtze River flows and where climate conditions are probably favorable for H. capsulatum growth6; it is worth noting that 86% of these cases were classified as disseminated, and in 52% of affected patients no underlying diseases were disclosed. India is another Asian country where H. capsulatum is known to be endemic, although the true prevalence of this mycosis is still underappreciated. The first case was reported as early as 1954, and since then several cases (mostly DPH, even in the absence of underlying immunosuppression) have been published.8–10 In India the majority of histoplasmosis cases were reported from the eastern and north-eastern part of the country, especially from Calcutta (West Bengal) and Assam. Interestingly, as observed for the highly endemic areas in North America, both states are crossed by long rivers: the Ganges and the Brahamaputra, respectively.8–10 Moreover, the fungus was isolated from the soil of the Gangetic plains.11 A histoplasmin skin-test positivity rate of 12.3% was reported in northern India between the 1950s and 1970s.12 It has been hypothesized that in India a large number of cases might be unrecognized for a long period caused by low awareness of the disease and misdiagnose as tuberculosis or leishmaniasis.8,10 Oral cavity ulcers and bilateral adrenal enlargement seem to be particularly frequent among Indian patients, whereas skin lesions were observed in only 8% of cases.8,10 Also in the review of Chinese patients skin involvement was reported in a small fraction of cases (6.6%) and the authors speculated about the low number of HIV-positive patients in their file records.6 High rates of skin involvement have been observed among HIV-positive patients from South America and Africa.13 Thailand is another country of South-east Asia where localized foci of H. capsulatum exist, and the fungus has been shown by using nested polymerase chain reaction of soil contamined with bat guano and chicken droppings from Chiang Mai, a geographic area where Penicillium marneffei is also endemic.14 In contrast to the Chinese and Indian experiences, DPH in Thailand has been observed almost exclusively among HIV-infected patients, with 1,253 cases reported from 1984 to 2010 to the Ministry of Public Health.14 Based on sporadic case reports of autochthonous histoplasmosis, isolation of the fungus from soil in bat-infested caves and histoplasmin skin test surveys, Malaysia, Indonesia, Myanmar, and the Philippines should also be considered areas with pockets of endemicity for histoplasmosis.15,16 Interestingly, in a recent survey conducted in Europe, cases of disseminated histoplasmosis were diagnosed among elderly United Kingdom residents who had served in World War II in India and Myanmar and who did not leave their country of origin for more than 50 years after returning home.17 In Australia, cases of indigenous histoplasmosis were reported as early as 1948, and the organism has been cultured from fowl yards and caves, although the exact ecology is poorly understood18; the majority of cases were reported from the Queensland and northern New South Wales regions, which are characterized by tropical and subtropical climate. These regions are also crossed by long rivers (the Dumaresq and Macintyre rivers). Outside Asia autochthonous cases of histoplasmosis have been reported sporadically from Italy,13,17 where studies conducted in the 1960s confirmed the presence of H. capsulatum in soil19 and animals,20 with the existence (confirmed with histoplasmin skin tests) of a pocket of endemicity along the Po River valley.21 Histoplasma capsulatum var. duboisii, characterized by a larger size (8–15 μm) and thicker walls than H. capsulatum var. capsulatum, is found in Madagascar and in central and western regions of sub-Saharan Africa (Malì, Chad, Niger, Nigeria, Democratic Republic of Congo, and Ghana). It is classically associated with skin, subcutaneous, and bone lesions, but disseminated disease has been described among HIV-positive patients22; because both pathogens coexist in Africa,13,17 it has been suggested that until the correct variety of the fungus has been identified African patients should not be described as affected by “African histoplasmosis.”17 In conclusion, our knowledge of the true worldwide distribution of H. capsulatum is still incomplete, and works such as that of Wang and coworkers are worthwhile. Improved access to diagnostic tests and increased awareness of the disease outside the well-known endemic areas will be helpful in redrawing the map of the geographic extent of this infection. Moreover, in an era of increasingly mobile people, physicians need to consider histoplasmosis in travelers and immigrants from the Indian subcontinent and South-east Asia in addition to regions traditionally considered endemic.

          Related collections

          Most cited references24

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Literature Review and Case Histories of Histoplasma capsulatum var. duboisii Infections in HIV-infected Patients

          Human histoplasmosis is caused by 2 varieties of Histoplasma. The most common variety worldwide is H. capsulatum var. capsulatum, which has been reported from many disease-endemic areas where HIV infection is prevalent. Histoplasmosis is more frequent in the United States (Ohio and Mississippi River valleys), but it is not unusual in other parts of the world, such as Africa ( 1 , 2 ). In the western and central regions of sub-Saharian Africa, H. capsulatum var. capulatum coexists with another variety, H. capsulatum var. duboisii, whose ecology and pathogenesis remain almost unknown. Cases due to H. capsulatum var. duboisii are scarce in Europe, and all are imported ( 3 ). Before the era of highly-active antiretroviral therapy (HAART), the prevalence of H. capsulatum var. capsulatum infections reached up to 30% of HIV-infected patients in hyperendemic areas of the southeastern part of the United States ( 4 ). The infection occurs more often in patients with a CD4 count 200/mm3 and undetectable viral load). In July 2007, she is doing well with a CD4 count of 700/mm3 and a still-undetectable viral load. Discussion H. capsulatum var. duboisii is also known as African histoplasmosis because it has only been described on that continent, mostly in central and western Africa. The prevalence of histoplasmosis due to variety duboisii has not been established in countries in these regions in HIV-negative patients. Fewer than 300 cases are reported in the literature ( 7 ). The reason it remains rare, despite the major HIV pandemic in Africa, is unknown. Potential explanations are that patients die from other causes before histoplasmosis develops ( 8 ) or that variety capsulatum is more virulent than variety duboisii. This situation is reminiscent of Cryptococcus gattii and C. neoformans. C. gattii is rarely identified in HIV-infected patients, in contrast with C. neoformans, whereas both are present in the environment in countries where the prevalence of HIV infection is high ( 9 ). However, variety capsulatum is frequent in Africa. No data on the relative frequency of those 2 varieties has been published. Skin reaction to histoplasmin in histoplasmosis-endemic areas showed a 3% prevalence ( 10 ), but variety capsulatum and variety duboisii were not able to be differentiated. Higher prevalence (≈35%) was found in rural populations, especially among farmers, traders, and cave guides ( 11 ). Histoplasmosis due to variety duboisii may be misdiagnosed in those areas because of physicians’ lack of awareness. The pathogenesis of African histoplasmosis remains unclear. The main route of acquisition could be airborne contamination from the soil, rarely direct inoculation. Variety duboisii is classically associated with cutaneous lesions (nodules, ulcers) and osteolytic bone lesions, especially affecting the skull, ribs, and vertebrae (Table 1) ( 12 , 13 ). Histopathologic examination shows granuloma with necrosis and suppuration. Disseminated disease is not uncommon and can involve every organ; however, the heart and central nervous system are unusual locations. A total of 17 cases have been reported thus far among HIV-infected patients, including the 3 cases described here ( 14 – 19 ). An additional case has been reported, but without detailed description, in a Ugandan patient diagnosed in Japan ( 20 ). Among the well-described cases (Table 1), most involved patients with poor immunologic status (mean CD4 count 55/mm3), which also occurs with histoplasmosis due to variety capsulatum ( 21 ). Most patients had disseminated infections, and only 4 patients died. The prognosis of disseminated infection in this context is close to the 20% mortality rate reported for disseminated histoplasmosis due to variety capsulatum among AIDS patients ( 21 ), but the few number of cases does not allow us to extrapolate the mortality rate related to variety duboisii. Epidemiologic information, clinical manifestations, and outcomes of immunocompetent versus HIV-infected patients infected with variety duboisii are compared in Table 2 ( 13 ). These data confirm the tropism of variety duboisii for lymph nodes, skin, and bones. It is noteworthy that the disease is often located in the lungs in HIV-negative patients, whereas HIV-infected patients have substantially more disseminated disease. The latter finding may be explained by immunodepression, poor access to the healthcare system for HIV-infected persons in Africa, and late diagnoses of histoplasmosis. Table 1 Description of HIV-infected patients with histoplasmosis due to Histoplasma capsulatum var. duboisii* Case no.† Age, y Sex Country Clinical findings CD4 count/mm3 Pathology Positive fungal culture Treatment Outcome 1 20 F Congo Skin lesions NR Skin – AmB 1 mg/kg/d, Itr 300 mg/d Relapse 2 44 M Congo Skin lesions, weight loss, lymph nodes, peritonitis NR Skin, pus – Ketoconazole 600 mg/d, AmB, Itr 300 mg/d Relapse 3 41 M Congo Skin lesions, weight loss, lymph nodes, hepatomegaly, splenomegaly NR Skin – AmB Death 4 65 M DRC Fever, weight loss, anemia NR Bone marrow Bone marrow, blood AmB Death 5 28 M DRC Fever, skin lesions, lymph nodes, weight loss, bone lesions NR Skin Skin Ketoconazole 600 mg/d NR 6 31 F Cameroon Septic shock 2 Bone marrow Bone marrow, blood ABLC 5 mg/kg/d, Itr 400 mg/d No relapse 7 29 M Liberia Skin lesions NR Skin Skin Itr 200 mg/d NR 8 43 F Guinea-Bissau Fever, weight loss, anemia, abdominal pain 68 Colon – Itr 400 mg/d No relapse 9 30 M Nigeria Fever, skin lesions, lymph nodes, anemia 2 Skin Skin AmB 1 mg/kg/d, Itr 400 mg/d Relapse 10 38 M DRC Fever, weight loss, lymph nodes 160 Lymph nodes Bone marrow, lymph nodes AmB No relapse 11 26 M Congo Fever, skin lesions, lymph nodes NR Lymph nodes – AmB 1 mg/kg/48 h No relapse 12 30 M Côte d’Ivoire Fever, weight loss, lymph nodes 6 Bone marrow – Itr 400 mg/d No relapse 13 50 F Nigeria Skin lesions, bone lesions NR Skin, bone – Fluconazole 100 mg/d No relapse 14 45 M Ghana Fever, weight loss, splenomegaly 24 Blood – AmB 0.7 mg/kg/d Death 15 37 M DRC Fever, lymph nodes 100 Lymph nodes – Itr 400 mg/d Death 16 41 M DRC Lymph nodes, skin lesions 50 Lymph nodes Lymph nodes Liposomal AmB, Itr 400 mg/d No relapse 17 2 F DRC Fever, skin lesions, bone lesions, blood 45 Skin, bone, blood Skin Liposomal AmB, fluconazole No relapse *NR, not reported; AmB, amphotericin B deoxycholate; Itr, itraconazole; DRC, Democratic Republic of Congo; ABLC, amphotericin B lipid complex.
†Cases 1–14 are from the literature review; cases 15–17 are personal cases; see text. Table 2 Comparison of clinical and microbiologic findings of HIV-infected and immunocompetent patients with histoplasmosis due to variety duboisii*† Characteristic HIV positive (n = 17) HIV negative (n = 20) Age, y (range) 35 (2–65) 34 (8–62) Sex (M:F) 12:5 19:1 Visceral localizations Lymph nodes 53 65 Skin 59 40 Bones 18 25 Lungs 0† 35† Gastrointestinal 12 5 Disseminated 85† 55† Clinical manifestations Fever 58† 15† Weight loss, asthenia, anorexia 54 30 Respiratory symptoms 0 20 Hepatosplenomegaly 12 15 Diagnosis sites Lymph nodes 24 45 Skin 48 35 Bone marrow 18 0 Bone 12 5 Gastrointestinal 6 5 Pus 6 25 Lung 0† 25† Mycologic diagnosis Direct examination 100 40 Culture 64 65 Blood culture 12 0 Treatment Amphotericin B 66 80 Ketoconazole 12 35 Itraconazole 64 20 Fluconazole 12 0 Outcome Relapse 12 40 Death 24 5 *Except where indicated, all values are percentages. HIV-negative patients are from Dupont et al. ( 13 ).
†p 200/mm3. The stability of immune improvement has to be confirmed for several months before prophylaxis is stopped ( 32 ). Recent data suggest that the risk for relapse is rare after 12 months of treatment with a sustained immunologic improvement (CD4 >150/mm3) ( 33 ). However, in our experience based on the management of 20 cases of histoplasmosis due to variety duboisii in patients considered immunocompetent ( 13 ), relapses may be observed several years after the first episode. Thus, prolonged follow-up is mandatory for every patient with histoplasmosis due to variety duboisii. Since HAART was introduced, the clinical and immunologic conditions of HIV-infected patients have dramatically improved, but physicians should now be aware of immune reconstitution inflammatory syndrome (IRIS) ( 34 ). As for many pathogens, both varieties of H. capsulatum can induce IRIS in HIV-infected patients, as recently reported by our group ( 6 ). The importance of the inflammatory reaction during IRIS contrasts with the mild one observed in the initial phase of the disease in severely immunocompromised patients and may require specific treatment. Thus, histoplasmosis due to variety duboisii in HIV-infected patient remains a rare clinical entity but diagnosis should not be discounted because of the HIV status of the patient. Physicians working in Africa should be aware of H. capsulatum var. duboisii as a potentially emerging infection in HIV-infected patients.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Histoplasmosis in Europe: report on an epidemiological survey from the European Confederation of Medical Mycology Working Group.

            The purpose of this survey was to systematically collect data on individuals with histoplasmosis in Europe over a 5-year period (from January 1995 to December 1999). This included information on where and how the infection was acquired, the patient's risk factors, the causative organism, how the infection was diagnosed and what therapy the patients received. Data were sent on a standardized survey form via a national convenor to the coordinator. During the survey, 118 cases were reported, with 62 patients having disseminated disease, 31 acute pulmonary infection, chronic pulmonary infection in 6 and localized disease in 2 patients. For 17 patients, the diagnosis of histoplasmosis was incidental, usually secondary to investigations for lung cancer. Most patients had travelled to known endemic areas, but 8 patients (from Italy, Germany and Turkey) indicated that they had not been outside their countries of origin and hence these cases appear to be autochthonous. Notable observations during the survey were the reactivation of the disease up to 50 years after the initial infection in some patients and transmission of the infection by a transplanted liver. Itraconazole was the most commonly used therapy in both pulmonary and disseminated disease. The observation of autochthonous cases of disease suggests that the endemic area of histoplasmosis is wider than classically reported and supports continued surveillance of the disease throughout Europe.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Disseminated histoplasmosis.

              To study the clinical features and natural history of disseminated histoplasmosis(DH) in India. We retrospectively analyzed the data obtained from the in-patient medical records of adults (age > 13 years) diagnosed to have DH during the period from January 1989 to December 1999. DH was diagnosed when histologically compatible intracellular organisms were present or Histoplasma capsulatum was obtained in culture from the extrapulmonary sites. Nineteen patients (18 male and 1 female) were diagnosed to have DH. Diabetes mellitus and HIV infection were the most common co-morbid conditions. Weight loss, fever and oropharyngeal ulcers were the commonest symptoms. Physical signs included hepatosplenomegaly, oropharyngeal ulcers and lymphadenopathy. The diagnosis was confirmed by histopathology and/or culture from the following sites: bone marrow, adrenal gland, lymph node, oropharyngeal ulcers, rectal mucosa and skin. Two patients were treated with Amphotericin B, 6 with various azoles and 3 had Amphotericin B followed by various azoles. Among the eleven treated, 7 were cured, 2 improved, 1 had a relapse and 1 patient died. DH is not uncommon in India and should be considered in the diagnosis of patients with prolonged fever, weight loss, oropharyngeal ulcers, hepatosplenomegaly, lymphadenopathy and adrenal enlargement. Correct diagnosis and treatment leads to a favourable outcome.
                Bookmark

                Author and article information

                Journal
                Am J Trop Med Hyg
                Am. J. Trop. Med. Hyg
                tpmd
                The American Journal of Tropical Medicine and Hygiene
                The American Society of Tropical Medicine and Hygiene
                0002-9637
                1476-1645
                04 June 2014
                04 June 2014
                : 90
                : 6
                : 982-983
                Affiliations
                Department of Clinical and Biomedical Sciences “Luigi Sacco,” III Division of Infectious Diseases, University of Milano, Milano, Italy
                Author notes
                * Address correspondence to Spinello Antinori, Department of Biomedical and Clinical Sciences, “ Luigi Sacco,” University of Milano, Italy. E-mail: spinello.antinori@ 123456unimi.it
                Article
                10.4269/ajtmh.14-0175
                4047757
                24778192
                4b0efcdc-9600-46fb-9fd7-d9aaa23e9913
                ©The American Society of Tropical Medicine and Hygiene

                This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

                History
                : 21 March 2014
                : 26 March 2014
                Categories
                Editorial

                Infectious disease & Microbiology
                Infectious disease & Microbiology

                Comments

                Comment on this article